Armour Thyroid in Women Over 65: What You Need to Know About Off-Label Use

What Is Armour Thyroid and Why Do Some Older Women Use It?

Armour Thyroid is porcine-derived desiccated thyroid that contains both thyroxine (T4) and triiodothyronine (T3) in a fixed ratio of roughly 4:1 by weight. The FDA grandfathered it under the 1938 Food, Drug, and Cosmetic Act, which means it has never gone through a modern new drug application. Levothyroxine (synthetic T4 alone) became the standard of care in the 1960s and remains what current American Thyroid Association guidelines recommend as first-line therapy for hypothyroidism.

So why do some women over 65 ask specifically about NDT?

Many report that levothyroxine alone did not resolve symptoms such as fatigue, brain fog, cold intolerance, or low mood, even with a "normal" TSH. The hypothesis is that some people cannot adequately convert T4 to active T3, and therefore benefit from a preparation that delivers T3 directly. A 2019 randomized trial published in the Journal of Clinical Endocrinology and Metabolism found that roughly 48.5% of participants preferred desiccated thyroid extract over levothyroxine for subjective well-being, with slightly greater weight loss on NDT, though the study was not powered to show hard outcomes. The trial included both men and women, and did not sub-analyze results for postmenopausal women specifically.

That evidence gap matters. A lot.

Why "Off-Label" Is the Right Label Here

When a clinician prescribes Armour Thyroid to a 68-year-old woman with persistent symptoms on levothyroxine, she is making a reasonable clinical judgment. She is also using a drug in a population with almost no dedicated trial data. The FDA has not reviewed Armour Thyroid through a modern efficacy and safety process. The drug exists in a regulatory gray zone, and prescribers in this age group are extrapolating from younger adult data. Your clinician should be honest with you about that.

How Aging Changes Thyroid Physiology in Women

Thyroid function does not simply decline with age. The picture is more complicated, and it differs by sex and by reproductive history.

TSH Rises Naturally After Menopause

Population studies show that TSH levels drift upward with age. Data from the NHANES III study documented that the median TSH in adults over 70 is higher than in younger adults, with a shift in the reference range upper limit from roughly 4.5 mIU/L to as high as 7.5 mIU/L in octogenarians. Treating a TSH of 5.5 mIU/L in a 72-year-old woman with no symptoms as though it represents the same clinical problem as a TSH of 5.5 mIU/L in a 38-year-old with fatigue and heavy periods may be wrong. The thyroid system recalibrates.

Estrogen also modulates thyroid-binding globulin (TBG). Before menopause, higher estrogen raises TBG, which increases total T4 measurements without necessarily changing free T4. After menopause, TBG falls, and so do total T4 levels, even when free T4 remains stable. This sex-specific pharmacokinetic interaction means that lab values in postmenopausal women need interpretation against postmenopausal norms, not reproductive-age norms. A free T4 in the low-normal range in a 66-year-old woman warrants different clinical thinking than the same number in a 32-year-old.

T3 Metabolism Slows With Age

The conversion of T4 to active T3 via deiodinase enzymes may decrease with age, as suggested by observational data showing lower serum T3 in older adults. This is part of the rationale some clinicians use to justify NDT in older women with persistent symptoms. The counter-argument is that Armour Thyroid delivers T3 in a fixed ratio and in a pulse rather than the steady physiological release produced by peripheral conversion, which creates pharmacokinetic risks that are more pronounced in women with age-related cardiac remodeling.

Bone Density Is a Central Concern

Postmenopausal women already face accelerated bone loss from estrogen withdrawal. The Women's Health Initiative and subsequent analyses documented that women lose roughly 1-2% of bone mineral density per year in the years immediately after menopause. Adding even mildly suppressed TSH from thyroid hormone over-treatment compounds that loss. A meta-analysis in JAMA Internal Medicine found that subclinical hyperthyroidism was associated with a significantly increased risk of hip fracture, with a hazard ratio of 1.36 in older adults. For postmenopausal women not on bone-protective therapy, this is not a trivial number.

Specific Risks of Armour Thyroid in Women Over 65

Cardiovascular Risk

The T3 in NDT is absorbed quickly and produces a transient peak in serum T3 roughly two to four hours after ingestion. A pharmacokinetic study published in Thyroid showed that a single dose of desiccated thyroid caused T3 levels to exceed the normal range in most participants within hours. In younger women with healthy hearts, this transient elevation may be tolerated. In a 70-year-old woman with subclinical coronary artery disease or diastolic dysfunction, the same spike raises the risk of atrial fibrillation and palpitations.

The American Heart Association has highlighted that even subclinical hyperthyroidism, defined as a suppressed TSH with normal T4 and T3, is associated with a higher risk of atrial fibrillation, especially in adults over 65. NDT, with its fixed T3 dose, makes it harder to avoid transient TSH suppression in this age group.

Dose Stability

Armour Thyroid's T4:T3 ratio (approximately 38 mcg T4 and 9 mcg T3 per 60 mg grain) does not match human thyroid output, which produces T4 and T3 in a ratio closer to 20:1. Every grain of Armour delivers T3 in a proportion that significantly exceeds what the human gland makes. Dose-for-dose comparisons between NDT and levothyroxine are imprecise, and in older women who may have renal or hepatic changes affecting clearance, small dosing errors can cause significant over-treatment.

Cognitive Effects

Thyroid hormone excess in older women can precipitate or worsen anxiety, insomnia, and cognitive instability. Women over 65 often present differently with thyrotoxicosis than younger women, showing apathy and cognitive decline rather than classic hyperactivity. A prospective cohort study in JAMA found that subclinical hyperthyroidism was associated with greater cognitive decline in older adults, though the study did not separate results by sex.

Who Is Armour Thyroid Right For (and Who Should Avoid It)

This framework is designed to help you and your clinician have a structured conversation about whether NDT is appropriate at your life stage and with your specific health history. It does not replace a clinical evaluation.

Potentially Appropriate: A Narrow Group

• Women 65-70 with confirmed central hypothyroidism (pituitary dysfunction), where TSH is unreliable as a monitoring target and free T4/T3 levels guide therapy
• Women with documented poor T4-to-T3 conversion (low serum T3 despite adequate levothyroxine dose and normal TSH), confirmed on two separate tests
• Women who have failed or cannot tolerate two separate levothyroxine formulations and a liothyronine (synthetic T3) trial
• Women with high bone mineral density at baseline (DXA T-score better than -1.0), no prior atrial fibrillation, and normal cardiac function on recent evaluation
• Women willing to self-monitor pulse and accept more frequent TSH and free T3 checks (every 6-8 weeks during any dose adjustment)

Not Recommended

• Women with osteoporosis (T-score at or below -2.5) or fragility fractures
• Women with atrial fibrillation, heart failure, or significant coronary artery disease
• Women on anticoagulants, where rate-related complications from thyroid excess are particularly hazardous
• Women with adrenal insufficiency (NDT can precipitate adrenal crisis in this setting)
• Women over 80, given very limited evidence and high sensitivity to T3 peaks
• Women whose TSH is already at or below 1.0 mIU/L on their current dose of levothyroxine

Dosing Armour Thyroid in Women Over 65: What the Evidence Supports

There are no randomized controlled trials specifically examining NDT dosing in women over 65. The following recommendations are extrapolated from general geriatric prescribing principles, the 2014 ATA hypothyroidism management guidelines, and pharmacokinetic data.

Starting Low and Titrating Slowly

Standard adult starting doses of Armour Thyroid (60 mg, or 1 grain) are too high for most women over 65. A starting dose of 15-30 mg daily (0.25-0.5 grain) is more appropriate. Dose increases should not exceed 15 mg every 6-8 weeks, and each increase should be followed by a TSH and free T3 check before proceeding.

TSH Targets in This Age Group

Most endocrinology guidance accepts a TSH target of 1.0-4.0 mIU/L for women aged 65-80. The British Thyroid Association guidelines suggest that the upper limit of acceptable TSH rises with age and that treatment of mildly elevated TSH in asymptomatic older adults may cause more harm than benefit. For women over 80, some experts accept a TSH of 4.0-6.0 mIU/L if symptoms are absent. A TSH below 1.0 mIU/L on NDT should prompt a dose reduction without exception.

Timing of Doses and Labs

Because NDT produces a T3 peak two to four hours post-dose, TSH and free T3 blood draws should be scheduled at least 8-12 hours after the last dose to avoid falsely suppressed TSH and falsely elevated T3. Morning dosing on an empty stomach, with no food for 30-60 minutes after, improves absorption consistency. Labs drawn on the day of ingestion can mislead dose decisions.

Monitoring Bone and Heart Alongside Thyroid Labs

Any woman over 65 starting or continuing NDT should have:

• A baseline DXA scan if one has not been done in the prior two years
• An annual DXA if TSH is consistently below 2.0 mIU/L
• A baseline ECG and annual pulse review
• Calcium and vitamin D levels checked, with supplementation if deficient

Armour Thyroid and Other Women's Health Conditions in This Age Group

Osteoporosis and Fracture Risk

Postmenopausal women on NDT face a double burden: bone loss from estrogen deficiency and potential additional loss from even mildly suppressed TSH. A study in the Journal of Bone and Mineral Research found that each 1 mIU/L decrease in TSH below the normal range was associated with a 2.4% decrease in femoral neck bone mineral density over four years. Women on NDT who also have low bone density should be evaluated for bisphosphonate or other antiresorptive therapy concurrently, not sequentially.

Cardiovascular Disease and Hormone History

Many postmenopausal women in their 60s and 70s have used menopausal hormone therapy (MHT). Oral estrogen raises TBG and increases levothyroxine requirements by roughly 25-50%. NDT requirements are affected similarly. The Menopause Society's clinical practice statement does not specifically address NDT co-prescription, but the pharmacokinetic interaction with estrogen-containing MHT applies to all thyroid hormone formulations. Women switching from oral to transdermal estrogen may need a downward dose adjustment of their thyroid replacement.

Cognitive Symptoms and the Symptom Overlap Problem

One reason older women seek NDT is persistent cognitive symptoms on levothyroxine. Brain fog, slow processing, and word-finding difficulty are common in postmenopausal women and have multiple causes including estrogen deficiency, sleep disruption, depression, metabolic syndrome, and early neurodegeneration. Attributing these symptoms solely to inadequate thyroid hormone replacement, and escalating NDT dose in response, is a genuine clinical hazard. A 2020 review in Thyroid concluded that there is insufficient evidence to recommend NDT over levothyroxine for cognitive outcomes in any age group. A thorough evaluation of other causes of cognitive symptoms should precede any NDT dose increase.

Pregnancy, Lactation, and Contraception

This section applies minimally to women over 65, as spontaneous pregnancy after 65 is exceedingly rare without donor egg technology. For women in their mid-60s who used assisted reproductive technology and are postmenopausal, standard post-ART thyroid monitoring applies.

If a woman aged 65 or older is using donor egg IVF or is in the immediate postmenopause transition (under 65 with surgical menopause), the following points are relevant:

• Armour Thyroid is FDA Pregnancy Category A based on older data. T4 and T3 do cross the placenta minimally in the first trimester, but adequate maternal thyroid hormone is essential for fetal neurological development. Any use during pregnancy should be supervised by a maternal-fetal medicine specialist and an endocrinologist together.
• Thyroid hormone requirements increase by approximately 30-50% during pregnancy, and NDT's fixed T4:T3 ratio makes titration during pregnancy more difficult than with levothyroxine alone. ACOG Practice Bulletin No. 223 recommends levothyroxine as the preferred formulation during pregnancy.
• NDT passes into breast milk in small amounts. Neonatal thyroid function should be monitored if a lactating woman uses NDT.
• Contraception: Women under 55 who remain premenopausal despite having hypothyroidism still require reliable contraception if they wish to avoid pregnancy. NDT itself does not interact with hormonal contraceptives, but hormonal contraceptives containing estrogen raise TBG and increase total T4, which may affect monitoring.

For the overwhelming majority of readers of this article, who are postmenopausal women over 65, contraception is not required and pregnancy risk from NDT is not clinically relevant.

What a Conversation With Your Clinician Should Cover

If you are over 65 and asking your provider about Armour Thyroid, here are the specific questions that will help you get a complete answer rather than a reflexive "no" or an uncritical "yes."

• What is my current free T3 level, and is it in the lower half of the normal range despite a normal TSH? (If yes, a conversion issue may be plausible.)
• What is my current DXA T-score, and has anyone calculated my FRAX fracture risk?
• Have I had an ECG in the past year, and does it show any evidence of atrial fibrillation?
• What is my current TSH target, and why was that number chosen for my age?
• If I try NDT, what dose would we start at, how often would you check labs, and what would be the criteria for stopping?
• Are there other explanations for my symptoms (sleep apnea, depression, perimenopause residual effects, early cognitive change) that should be ruled out first?

As WomanRx reviewer Dr. Maya Okafor, MD, put it during editorial review of this article: "The women I see over 65 who are most harmed by NDT are the ones whose symptoms were never really about the thyroid in the first place. Before we change the formulation, we should make absolutely sure we have the right diagnosis and the right target. A TSH of 3.8 mIU/L in a 71-year-old with fatigue is not the same clinical problem as a TSH of 3.8 mIU/L in a 34-year-old with the same complaint."

The Evidence Gap Women Deserve to Know About

Women over 65 have been under-represented in thyroid hormone trials throughout the history of clinical research. The 2019 NDT-versus-levothyroxine trial that is most frequently cited had a mean participant age of 52 and did not report subgroup analyses for women over 65 or for postmenopausal women separately. The trial enrolled 70 participants, which is far too small to detect differences in hard outcomes like fracture or atrial fibrillation.

No randomized controlled trial has been conducted specifically in women over 65 comparing NDT to levothyroxine for any outcome. This is the honest answer to the question this article set out to answer. What clinicians are doing when they prescribe NDT in this age group is applying clinical judgment, pharmacokinetic reasoning, and individualized risk-benefit analysis to a therapeutic space that research has not yet examined directly.

That is not inherently wrong. Medicine often requires prescribing ahead of the trials. What it does mean is that informed consent for older women considering NDT must explicitly acknowledge that the evidence base is thin, that risks are extrapolated from younger populations and from general hyperthyroidism data, and that monitoring must be more frequent than for younger adults.

Women deserve that transparency. They should not have to ask for it.